Cargando…

Identification of cell surface targets for CAR-T cell therapies and antibody–drug conjugates in breast cancer

BACKGROUND: Two promising therapeutic strategies in oncology are chimeric antigen receptor-T cell (CAR-T) therapies and antibody–drug conjugates (ADCs). To be effective and safe, these immunotherapies require surface antigens to be sufficiently expressed in tumors and less or not expressed in normal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schettini, F., Barbao, P., Brasó-Maristany, F., Galván, P., Martínez, D., Paré, L., De Placido, S., Prat, A., Guedan, S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038941/ https://www.ncbi.nlm.nih.gov/pubmed/33838601 http://dx.doi.org/10.1016/j.esmoop.2021.100102

Ejemplares similares

A perspective on the development and lack of interchangeability of the breast cancer intrinsic subtypes
por: Schettini, Francesco, et al.
Publicado: (2022)

Pan-Cancer Analysis Identifies Tumor Cell Surface Targets for CAR-T Cell Therapies and Antibody Drug Conjugates
por: Li, Xinhui, et al.
Publicado: (2022)

CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge
por: Guedan, Sonia, et al.
Publicado: (2018)

Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies
por: Prat, Aleix, et al.
Publicado: (2021)

Frequency and spectrum of PIK3CA somatic mutations in breast cancer
por: Martínez-Sáez, Olga, et al.
Publicado: (2020)

Gene expression profiles of breast cancer metastasis according to organ site
por: Brasó‐Maristany, Fara, et al.
Publicado: (2021)

Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis
por: Schettini, F., et al.
Publicado: (2023)

Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive/HER2-negative metastatic breast cancer with visceral crisis: A case report
por: Schettini, Francesco, et al.
Publicado: (2022)

CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape
por: Rodriguez-Garcia, Alba, et al.
Publicado: (2020)

Enhancing T cell persistence of CAR-redirected T cells in solid tumors
por: Guedan, Sonia, et al.
Publicado: (2014)

P836: ANTIBODY-DRUG CONJUGATES AS POTENTIAL CAR-T CELL SPECIFIC OFF-SWITCH IN MULTIPLE MYELOMA
por: Bielowski, Anna, et al.
Publicado: (2023)

Beyond Bruton’s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody–drug conjugates, CAR T-cells, and novel agents
por: Jain, Neeraj, et al.
Publicado: (2023)

Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer
por: Díaz-Gil, Laura, et al.
Publicado: (2021)

The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma
por: Jiang, Vivian Changying, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of CAR T-Cell Therapies vs Antibody Drug Conjugates for Patients with Advanced Multiple Myeloma
por: Kapinos, Kandice A., et al.
Publicado: (2023)

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
por: Schettini, Francesco, et al.
Publicado: (2021)

Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
por: Schettini, Francesco, et al.
Publicado: (2023)

Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer
por: Prat, Aleix, et al.
Publicado: (2022)

Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy
por: Chic, Nuria, et al.
Publicado: (2021)

HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial
por: Guarneri, Valentina, et al.
Publicado: (2022)

Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy
por: Martínez-Sáez, Olga, et al.
Publicado: (2021)

Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease
por: Isola, Ignacio, et al.
Publicado: (2021)

DEMONSTRATION OF SURFACE ANTIGENS AND PINOCYTOSIS IN MAMMALIAN CELLS WITH FERRITIN-ANTIBODY CONJUGATES
por: Easton, John M., et al.
Publicado: (1962)

Surface conjugation of antibodies improves nanoparticle uptake in bronchial epithelial cells
por: Luks, Valerie L., et al.
Publicado: (2022)

Fate of Antibody-Drug Conjugates in Cancer Cells
por: Chalouni, Cécile, et al.
Publicado: (2018)

Computational Construction of Antibody–Drug Conjugates Using Surface Lysines as the Antibody Conjugation Site and a Non-cleavable Linker
por: Filntisi, Arianna, et al.
Publicado: (2014)

CAR T-Cell Cancer Therapy Targeting Surface Cancer/Testis Antigens
por: Jakobsen, Mie K., et al.
Publicado: (2020)

Impact of the conjugation of antibodies to the surfaces of polymer nanoparticles on the immune cell targeting abilities
por: Lee, Na Kyeong, et al.
Publicado: (2021)

Targeting CD56 with an antibody–drug conjugate in Merkel cell carcinoma
por: Leiendecker, L., et al.
Publicado: (2021)

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
por: Brasó-Maristany, Fara, et al.
Publicado: (2020)

Adverse events of antibody–drug conjugates on the ocular surface in cancer therapy
por: Domínguez-Llamas, Sandra, et al.
Publicado: (2023)

Antibody-Oligonucleotide Conjugates: A Twist to Antibody-Drug Conjugates
por: Dugal-Tessier, Julien, et al.
Publicado: (2021)

A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody–Drug Conjugate for Targeting Melanoma
por: Shi, Jing, et al.
Publicado: (2023)

Conduit CAR: Redirecting CAR T-Cell Specificity with A Universal and Adaptable Bispecific Antibody Platform
por: Borrok, M. Jack, et al.
Publicado: (2022)

Antibody-Drug Conjugates Used in Breast Cancers
por: Abbas, Aram J., et al.
Publicado: (2021)

Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma
por: Martínez Bedoya, Darel, et al.
Publicado: (2021)

Engineering CAR-T cells
por: Zhang, Cheng, et al.
Publicado: (2017)

CARs and Drugs: Pharmacological Ways of Boosting CAR-T-Cell Therapy
por: Harrer, Dennis Christoph, et al.
Publicado: (2023)

CAR T Cells: Cancer Cell Surface Receptors Are the Target for Cancer Therapy
por: Shademan, Behrouz, et al.
Publicado: (2022)

Promoter usage regulating the surface density of CAR molecules may modulate the kinetics of CAR-T cells in vivo
por: Ho, Jin-Yuan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3glr5fp5u1rp1v0ftdfl939duj